Pharmacotherapy for the obese patient.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 19501251.
- Also identified by DOI 10.1016/j.pop.2009.01.004.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The long-term safety of many antiobesity pharmacologic regimens has not been adequately evaluated. If recommended and prescribed, pharmacologic agents should be an adjunct to a structured diet and exercise regimen. Unfortunately, weight gain after discontinuation of antiobesity agents is common. In addition, the effect of weight loss obtained through the use of pharmacotherapeutic agents on overall morbidity and mortality has not been established.
Medical subject headings
- Anti-Obesity Agents
- Appetite Depressants
- Obesity